How would you define the success of GSK's Voltaren arthritis pain gel?

Introduction

Defining the success of GSK's Voltaren arthritis pain gel requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge effectively, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Voltaren is a topical nonsteroidal anti-inflammatory drug (NSAID) gel used for arthritis pain relief. It's an over-the-counter (OTC) product that was previously available only by prescription in the US. Key stakeholders include patients seeking pain relief, healthcare providers, pharmacists, and GSK shareholders.

The user flow typically involves:

1. Recognizing pain and deciding to seek relief
2. Purchasing the product (online or in-store)
3. Applying the gel as directed
4. Experiencing pain relief and potentially repurchasing

Voltaren fits into GSK's broader strategy of expanding its consumer health portfolio, particularly in the pain relief segment. It competes with other topical pain relievers like Bengay and Icy Hot, as well as oral pain medications.

In terms of product lifecycle, Voltaren is in the growth stage in the OTC market, having transitioned from prescription-only status relatively recently.

As a physical product, key considerations include:

• Distribution channels (pharmacies, supermarkets, online retailers)
• Shelf-life and storage requirements
• Retail partnerships and placement strategies